B
Broken String Biosciences
Enhancing the safety of cell and gene therapies through comprehensive genome stability assessments
About Broken String Biosciences
Broken String Biosciences is a genomics company that operates in the biotechnology sector. The company is developing a technology platform that speeds up the characterization of new genome editing technologies. This is expected to pave the way for the next generation of cell and gene therapies. The company's vision is to make these therapies safer, more efficient, and affordable for patients.
The company's primary technology, INDUCE-seq™, is a DNA break mapping technology. This technology provides detailed information about how genome editors interact with and modify our genomes. This information is crucial for the efficient development of new genome editing systems and will open up many new targets within the genome for therapeutic development.
Broken String Biosciences serves clients in the biotechnology and healthcare sectors, including scientific leaders and world-renowned organizations. The company's business model is based on partnerships and collaborations to further develop and apply its technology.
The company generates revenue by licensing its technology to other companies and research institutions. It also makes money by providing services related to its technology, such as data analysis and consulting.
Broken String Biosciences is backed by Illumina and Tencent and is based at the Wellcome Genome Campus in Cambridge, UK. The company recently appointed Gavin Burns as Vice President of Quality and Operations, indicating a focus on quality assurance and operational efficiency.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United Kingdom
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 71.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Sequencing, Core AI, Spinout, Genome Engineering, AI Drug Discovery, Techbio, Hard Tech
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2025 | $5.9M | $77M | Undisclosed | ↗ |
| GRANT✓Other financing | Jul 2025 | $331K | — | UK Research and Innovation | — |
Growth signals
Latest recorded traffic for Broken String Biosciences is 5K monthly website visits, up 100% over the last three months. Broken String Biosciences's team grew 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Illumina Ventures
UK Research and Innovation
Series A4 investors entered at this stage
Mérieux Equity Partners
Dieter von Holtzbrinck Ventures
HERAN Partners
Tencent
Other known investors2 additional known investors
Cardiff University
First In Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Broken String Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Broken String Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.